SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Sep 26, 2019
PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: Sept. 26, 2019 · CIK: 0001614744 · Accession: 0001213900-19-018932
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233795
Letter
Kitov Pharma Ltd.
One Azrieli Center, Round Tower
132 Menachem Begin Road
Tel Aviv, 6701101, Israel
September 26, 2019
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
RE: Kitov Pharma Ltd.
Registration Statement on Form F-3
Originally filed September 16, 2019
File No. 333-233795
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to 5:00 p.m., Eastern Time on September 27, 2019, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharma Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Kitov Pharma Ltd.
One Azrieli Center, Round Tower
132 Menachem Begin Road
Tel Aviv, 6701101, Israel
September 26, 2019
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
RE:
Kitov Pharma Ltd.
Registration Statement on Form F-3
Originally filed September 16, 2019
File No. 333-233795
Ladies and Gentlemen:
Pursuant to Rule 461 of
the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities
Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the effective date
of the above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to 5:00 p.m., Eastern
Time on September 27, 2019, or as soon thereafter as practicable.
Should any member of the
staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact
our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharma Ltd.
By:
/s/ Isaac Israel
Isaac Israel
Chief Executive Officer